title: Comparison of the treatment results after conventional and myeloablative chemotherapy in patients with poor prognosis Ewing's sarcoma family tumors - single center experience.
abstract: OBJECTIVE
  To compare the survival of patients with poor prognosis Ewing's sarcoma family tumors (EFT) after conventional and myeloablative chemotherapy treated at our hospital in a period of 25 years.
  
  
  METHODS
  Fifty-seven patients were treated between 1985 and 2010. The patients were separated into 3 groups. Group A included patients (n=20) treated with conventional chemotherapy between 1985 and 1997. Group B patients (n=22) were treated with conventional chemotherapy protocols between 1997 and 2010; and group C patients (n=15) were treated in the same period of time with conventional chemotherapy and subsequent myeloablative chemotherapy with hematopoietic stem cell transplantation (HSCT).
  
  
  RESULTS
  In group A patients the 5-year overall survival (OS) was 25% and the disease-free survival (DFS) 15%; in group B patients they were 27.27% and 18.8% (p=0.31) and in group C patients 33.3% and 20% (p=0.58), respectively.
  
  
  CONCLUSIONS
  More intensive chemotherapy, including myeloablative chemotherapy plus HSCT, is a curative option for patients with poor-prognosis EFT, but the survival still remains unsatisfactory.
authors: Specialized Children's Oncohaematology Hospital, Sofia, Bulgaria. b.avramova@sbaldohz.com
authors: B
authors: B
authors: Avramova
authors: M
authors: M
authors: Jordanova
authors: D
authors: D
authors: Konstantinov
authors: I
authors: I
authors: Hristozova
authors: I
authors: I
authors: Shtarbanov
authors: Dr
authors: D
authors: Bobev
mesh_terms: D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000401:mortality